扶正化瘀片基于miR-122/IL-10因子治疗肝纤维化  

Fuzheng Huayu Tablets in Treatment of Liver Fibrosis Based on miR-122/IL-10 Factor

作　　者：张海丛[1] 邵明亮[1] 张巍[1] 袁文芳[1] 侯桂英[1] 李志锁 王蕊[3] ZHANG Haicong;SHAO Mingliang;ZHANG Wei;YUAN Wenfang;HOU Guiying;LI Zhisuo;WANG Rui(The Fifth Hospital of Shijiazhuang City,Shijiazhuang Hebei China 050000;Hospital of Gaoyi County,Gaoyi Hebei China 051330;Hebei University of Chinese medicine,Shijiazhuang Hebei China 050000)

机构地区：[1]石家庄市第五医院,河北石家庄050000 [2]高邑县医院,河北高邑051330 [3]河北中医学院,河北石家庄050000

出　　处：《中医学报》2019年第6期1317-1321,共5页Acta Chinese Medicine

基　　金：河北省高等学校科学技术研究项目(ZD2018-021);河北省科技计划项目(17277730D)

摘　　要：目的:探讨扶正化瘀片对肝纤维化患者的软坚散结作用,是否与miR-122/白细胞介素-10(interleukin-10,IL-10)通路调节作用有关。方法:慢性肝炎肝纤维化患者75例,随机分为观察组41例和对照组34例,另留取健康体检者30例为健康组。对照组给予恩替卡韦治疗,观察组给予恩替卡韦联合扶正化瘀片抗纤维化联合治疗。治疗前后同时测定各组血清中miR-122与IL-10mRNA的表达,采用ELISA法测定肝细胞超氧化物歧化酶(superoxide orgotein dismutase,SOD)、活性氧(reactive oxygen species,ROS)活性,结合临床肝纤维化四项[Ⅲ型前胶原氨端肽(procollagenⅢ,PCⅢNP)、IV型胶原(collagenⅣ,CIV)、透明质酸(hyaluronic acid,HA)、层粘连蛋白(laminin,LN)]以及常规病理评价。结果:进行Ishak纤维化评分结果发现,治疗前对照组、观察组平均为5.5分;治疗后对照组平均为5.1分,观察组为3.5分,两组比较,差异有统计学意义(P<0.05)。观察组肝纤维化CIV、HA较对照组明显下降,两组比较,差异有统计学意义(P<0.05)。观察组治疗后IL-10与对照组比较,差异有统计学意义(P<0.05)。观察组治疗后ROS较对照组明显下降(P<0.05),SOD较对照组明显上升(P<0.05)。结论:扶正化瘀片可以调节miR-122/IL-10,从而控制患者的肝纤维化进展,具有明显调节作用。Objective:To investigate the softening and dispersing effect of Fuzheng Huayu Tablet combined with antiviral therapy on hepatic fibrosis patients,and whether it is related to the regulation of miR1-22/IL-10 pathway.Methods:75 patients with chronic hepatitis and hepatic fibrosis were randomly divided into an experimental group(45 cases)and a control group(30 cases),and 30 healthy persons were selected as the healthy group.The control group received antiviral treatment and protective liver cell therapy according to clinical routine.The experimental group was given the Fuzheng Huayu tablet 1.5 g/times,and 3 times a day for 48 weeks.Before and after treatment were measured serum miR-122 and interleukin(IL-10)mRNA expression,ELISA liver cell Superoxide dismutase(SOD),Reactive oxygen species(ROS)activity,combined with clinical liver fibrosis four(PCIIINP,CIV,HA,LN)and pathological evaluation.Results:The Ishak fibrosis score suggests that before treatment the control group and the experimental group averaged 5.5 points.After treatment the control group had an average of 5.1 points,the experimental group was 3.5 points,and the statistical comparison between the two groups showed significant difference(P<0.05).The liver fibrosis CIV and HA in the experimental group were lower in the control group,and there was a significant difference between the groups(P<0.05).The IL-10 in the experimental group was significantly different from that in the control group(P<0.05).After treatment in the experimental group ROS was significantly lower than that in the control group(P<0.05),and SOD increased significantly in the control group(P<0.05).Conclusion:Fuzheng Huayu Tablet can regulate miR-122/IL-10,and can control the progression of hepatic fibrosis in patients,with significant biological regulation effect.

关 键 词：肝纤维化 扶正化瘀片 恩替卡韦 转化生长因子 白细胞介素-10 软坚散结法 

分 类 号：R259.752[医药卫生—中西医结合]